

## Medicines Patent Pool Governance Board Meeting #32

November 2<sup>nd</sup> and 3<sup>rd</sup>, 2021  
Hybrid meeting due to Covid-19

### Attendees

#### **Governance Board Members:**

Marie-Paule Kieny (Chair), Mojisola Christianah Adeyeye, Manica Balasegaram, Patrizia Carlevaro, Jinliang Li, Peter Maybarduk, John-Arne Røttingen, Maximiliano Santa Cruz, and Alexandra Volgina.

#### **Non-voting members:**

Peter Beyer – EAG Chair, Marion (Amy) Dietterich – WIPO Observer, Mariangela Batista Galvão Simão – WHO Observer, Antony Scott Taubman – WTO observer, Jan Akko Eleveld – Unitaaid Project Team, Luis Pizarro de Trenqualye – Unitaaid Executive Team, and Karin Timmermans - Unitaaid Strategy Team.

#### **Medicines Patent Pool Foundation Management Team:**

Charles Gore – Executive Director, Karine Belondrade – Head of Strategy, Operations and Resource Mobilisation, Esteban Burrone – Head of Policy, Vincent Chauvin – CFO, Head of Human Resources, Gelise McCullough – Head of Communications, Sandra Nobre – Head of Business Development, Chan Park – General Counsel, and Agnese Tonnina – Grants and Operations Manager.

### Summary of Decisions

#### **The Governance Board of the Medicines Patent Pool:**

1. Approves the agenda of the Governance Board Meeting #32.
2. Agrees that the level of Board oversight conducted through the various reporting mechanisms is appropriate and that donor reports can be submitted directly by the management to donors. The Finance and Management Committee will monitor that they are submitted by the deadline through the operational framework and reports to the Board.
3. Approves the inclusion of biotherapeutics in the scope of MPP's work on medicines that are either on the WHO EML or have strong potential for future inclusion. MPP's prioritisation framework should be adapted to cater for biotherapeutics, based on the findings of the Biologics report.
4. Approves all the changes resulting from the Management review of the risk register and requests the Management to review the global mRNA vaccine Technology

Transfer Hub risk matrix and transfers relevant risks to the MPP risk register for review by the Governance Committee in March 2022.

5. Invites Patrizia Carlevaro to serve for another 2-year term until November 30<sup>th</sup>, 2023.
6. Approves the appointment of Jennifer Cohn as EAG Infectious Disease Expert.
7. Approves the appointment of Ernst & Young as statutory auditors for the next five years.
8. Approves the changes to the HR Policy pending amends requested by the Board.
9. Approves the Operational KPI Framework for 2021-2022.
10. Adopts the changes to the Transparency Policy with the following amendment to section 2.1.5: replace “to engage in frank internal deliberations” with “to decide on most appropriate strategy”.